These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33369772)

  • 1. Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study.
    Préterre J; Visentin J; Saint Cricq M; Kaminski H; Del Bello A; Prezelin-Reydit M; Merville P; Kamar N; Couzi L
    Clin Transplant; 2021 Mar; 35(3):e14207. PubMed ID: 33369772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
    Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
    Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
    Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 10. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J; Cristelli MP; Viana LA; Ficher KN; Nakamura MR; Proença H; Dreige YC; de Marco R; de Lima MG; Foresto RD; Aguiar WF; Medina-Pestana J; Tedesco-Silva H
    Transplantation; 2024 Jan; 108(1):261-275. PubMed ID: 37525373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
    Asleh R; Clavell AL; Pereira NL; Smith B; Briasoulis A; Alnsasra H; Kremers WK; Habermann TM; Otley CC; Li X; Edwards BS; Stulak JM; Daly RC; Kushwaha SS
    J Am Coll Cardiol; 2019 Jun; 73(21):2676-2688. PubMed ID: 31146812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
    Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review.
    Zhao DQ; Li SW; Sun QQ
    Transplant Proc; 2016; 48(1):3-9. PubMed ID: 26915834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to sirolimus in kidney-pancreas and pancreas transplantation.
    Matias P; Araujo MR; Romão JE; Abensur H; Noronha IL
    Transplant Proc; 2008 Dec; 40(10):3601-5. PubMed ID: 19100448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.